Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the top-line with revenue of $28.1M vs. $29.0M expected, reflecting a deceleration in bone fusion product sales (-8% YoY). While GAAP Net Loss of $0.41M and EPS of -$0.05 missed the mean estimates, gross margin remained exceptionally strong at 93%, exceeding the 90% consensus. The announcement of the acquisition by MIMEDX serves as the primary near-term catalyst, overshadowing operational variance.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Sanara Medtech(SMTI) the Revenue is 28.14 M (+8.93%), Miss estimate;the EBIT is 1.78 M (+5779%), Miss estimate;the EPS is -0.05 (+78.26%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.03B8.93%
0.03B12.08%
-0.00B3.15%
EBITMiss expectations
0.00B5779.04%
0.00B5953.27%
-0.00B174.23%
EPSMiss expectations
-0.0578.26%
-0.02589.13%
-0.025010.87%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf